Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Fudan University
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histology-confirmed metastatic CRC (mCRC)
Disease progression on standard therapy with at least two lines of chemotherapy, including fluorouracil, oxaliplatin, and irinotecan with or without biologics such as bevacizumab and cetuximab
Fruquintinib administered as salvage treatment
Age: 18-75 years old
Informed consent
You may not be if
Liver or kidney dysfunction, or other conditions unsuitable for chemotherapy
Fruquintinib and/or TAS-102 administration as second-line treatment
Drug administration stopped after less than two cycles
Clareo Health | Fruquintinib Combined With TAS-102 in Refractory Metastatic Colorectal Cancer
